Madrigal Pharmaceuticals, Inc. financial data

Symbol
MDGL on Nasdaq
Location
200 Barr Harbor Drive, Suite 400, West Conshohocken, PA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 473 % -34.5%
Quick Ratio 24 % +674%
Debt-to-equity 58.5 % +68.1%
Return On Equity -41.5 % +42.2%
Return On Assets -26.2 % +50.8%
Operating Margin -41.5 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 22.7M shares +4.13%
Common Stock, Shares, Outstanding 22.7M shares +4.12%
Entity Public Float 5.1B USD +61.5%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 22.5M shares +3.39%
Weighted Average Number of Shares Outstanding, Diluted 22.5M shares +3.39%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 137M USD
Revenue from Contract with Customer, Excluding Assessed Tax 741M USD +362%
General and Administrative Expense 108M USD +125%
Operating Income (Loss) -307M USD +43.9%
Net Income (Loss) Attributable to Parent -289M USD +44.3%
Earnings Per Share, Basic -12 USD/shares +49%
Earnings Per Share, Diluted -12 USD/shares +49%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 296M USD +27.1%
Cash, Cash Equivalents, and Short-term Investments 1.11B USD +11.1%
Accounts Receivable, after Allowance for Credit Loss, Current 113M USD +272%
Inventory, Net 69.3M USD +695%
Assets, Current 1.35B USD +26.6%
Property, Plant and Equipment, Net 2.91M USD +28.4%
Operating Lease, Right-of-Use Asset 5.39M USD +114%
Assets 1.36B USD +26.9%
Accounts Payable, Current 44.9M USD -2.23%
Employee-related Liabilities, Current 51.1M USD +72.2%
Accrued Liabilities, Current 345M USD +164%
Liabilities, Current 391M USD +120%
Operating Lease, Liability, Noncurrent 5.57M USD +373%
Liabilities 737M USD +149%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.07M USD -16%
Retained Earnings (Accumulated Deficit) -2.03B USD -16.6%
Stockholders' Equity Attributable to Parent 626M USD -19.5%
Liabilities and Equity 1.36B USD +26.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -88.9M USD +40.4%
Net Cash Provided by (Used in) Financing Activities 8.64M USD -98.5%
Net Cash Provided by (Used in) Investing Activities 164M USD +67.1%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 22.7M shares +4.12%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 83.6M USD -84%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 301M USD +26.5%
Deferred Tax Assets, Valuation Allowance 509M USD +32.8%
Deferred Tax Assets, Gross 509M USD +32.8%
Operating Lease, Liability 2M USD +16.8%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -289M USD +44.1%
Lessee, Operating Lease, Liability, to be Paid 2.22M USD +19.4%
Operating Lease, Liability, Current 1.08M USD +23.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.07M USD +124%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.15M USD +22.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 221K USD +49.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 446K USD
Deferred Tax Assets, Operating Loss Carryforwards 214M USD +76.4%
Preferred Stock, Shares Issued 2.37M shares 0%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 2.37M shares 0%
Depreciation, Depletion and Amortization 379K USD +126%
Deferred Tax Assets, Net of Valuation Allowance 217K USD +85.5%
Share-based Payment Arrangement, Expense 90M USD +16.8%
Interest Expense 3.3M USD -14.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%